Insider Trading Activity Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) – Insider Bought 4,233 shares of Stock

19

Insider Trading Activity For Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)

Barbara White , Insider of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) reportedly Bought 4,233 shares of the company’s stock at an average price of 9.49 for a total transaction amount of $40,171.17 SEC Form

Insider Trading History For Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)

  • On 11/25/2014 Sean F Moran, CFO, bought 3,000 with an average share price of $3.05 per share and the total transaction amounting to $9,150.00. View SEC Filing
  • On 11/25/2014 Mark Tepper, Insider, bought 2,000 with an average share price of $3.05 per share and the total transaction amounting to $6,100.00. View SEC Filing
  • On 11/26/2014 Sean F Moran, CFO, bought 1,000 with an average share price of $3.05 per share and the total transaction amounting to $3,050.00. View SEC Filing
  • On 11/26/2014 Barbara White, Insider, bought 13,400 with an average share price of $3.00 per share and the total transaction amounting to $40,200.00. View SEC Filing
  • On 11/28/2014 Barbara White, Insider, bought 19,933 with an average share price of $3.00 per share and the total transaction amounting to $59,799.00. View SEC Filing
  • On 12/1/2014 Barbara White, Insider, bought 16,448 with an average share price of $3.00 per share and the total transaction amounting to $49,344.00. View SEC Filing
  • On 12/2/2014 Sean F Moran, CFO, bought 1,000 with an average share price of $3.03 per share and the total transaction amounting to $3,030.00. View SEC Filing
  • Analyst Ratings For Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)
    These are 4 Buy Ratings .
    The current consensus rating for Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is Buy (Score: 3.00) with a consensus target price of $17.00 , a potential (77.08% upside)

    Analyst Ratings History For Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)

    • On 11/15/2016 JMP Securities Boost Price Target of rating Outperform with a price target of $9.00 to $20.00
    • On 11/30/2016 Aegis Reiterated Rating Buy with a price target of $12.00
    • On 3/12/2017 Noble Financial Reiterated Rating Buy
    • On 3/14/2017 Cantor Fitzgerald Reiterated Rating Buy with a price target of $17.00

    About Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)
    Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. Its product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis. Resunab is in Phase II clinical stage for the treatment of Systemic Lupus Erythematosus.

    Recent Trading Activity for Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)
    Shares of Corbus Pharmaceuticals Holdings Inc closed the previous trading session at 10.30 up +0.70 7.29% with 1,151,876 shares trading hands.

    An ad to help with our costs